American and French scientists have concluded that Plitidepsin, which is marketed under the name Aplidin, has shown serious promising in fighting COVID-19 infections. Spanish newspaper El Periódico reported on Tuesday that the anti-virual drug underwent trials in France and the United States, and scientists noted that it was able reduce the viral load of COVID-19 by 99 percent. After the studies confirmed the effectiveness of the drug, the producing company’s shares rose in the stock market by 15 percent. El Periódico reported that in the study, two types of animals infected with coronavirus showed a decrease in viral reproduction and “viral load” in the lungs after being administered Aplidin. The researchers confirmed that the activity of the anti-COVID-19 compound Plitidepsin showed both powerful anti-viral properties and limited “toxicity”.

Source: Egypt Independent January 27, 2021 09:11 UTC